Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEUROPA

Financiado

Non invasive dynamic neural control by laser based technology

Europe faces an enormous human toll of brain disorders, with an estimated 83 million people affected, and economic costs amounting to approximately €800 billion. Drug treatments for brain disorders prove often less than effective... ver más

31/07/2023

ASTON U

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ASTON UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 9 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-07-31

FETOPEN-01-2018-2019-2020: FET-Open Challenging Current Thinki...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

ASTON U

1.01M€ | Lider

ABENGOA HIDRÓGENO

327.61K€ | Participante

UOULU

516.89K€ | Participante

QED FILM STAGE PRODUCTIONS...

190.99K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2013-45343-P NEUROMODULACION MEDIANTE TECNICAS NO INVASIVAS Y SU APLICACI... 212K€ Cerrado

TIMS Deep Brain Neuromodulation using Temporal Interference Magne... 150K€ Cerrado

PID2021-128204OA-I00 EFECTOS DE LA ESTIMULACION TRANSCRANEAL POR CORRIENTE DIRECT... 75K€ Cerrado

SAF2017-90713-REDT RED ESPAÑOLA DE ESTIMULACION CEREBRAL 19K€ Cerrado

SAF2017-86246-R ESTIMULACION TRANSCRANEAL POR CAMPO MAGNETICO ESTATICO EN LA... 182K€ Cerrado

UNST13-1E-2177 Estimulación transcraneal no invasiva eléctrica (tDCS) y mag... 147K€ Cerrado

Duración del proyecto: 46 meses Fecha Inicio: 2019-09-24
Fecha Fin: 2023-07-31

Líder del proyecto

ASTON UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Descripción del proyecto Europe faces an enormous human toll of brain disorders, with an estimated 83 million people affected, and economic costs amounting to approximately €800 billion. Drug treatments for brain disorders prove often less than effective with a lack of selective cell targeting. A failure to develop new drugs has led major Pharmaceutical companies to withdraw from CNS drug development in recent years. Methods such as Transcranial Magnetic Stimulation or Deep Brain Stimulation have displayed some therapeutic efficacy, however they are non-selective and/or invasive. It is therefore clear that with a failure of conventional therapy, a new approach is necessary, and development of new technology. NEUROPA will directly tackle this issue. An ideal treatment would be one where activity in specific implicated neuronal networks could be selectively modulated. To be relevant to human disorders the therapy should enable the long-term modulation of dysfunctional networks. For potential widespread use in patients the intervention and monitoring of effects on network activity should also be non-invasive. NEUROPA will develop a new Phytoptogenetics technology: novel Phytochromes that will enable modulation of expression of specific genes, selectively and non-invasively delivered and targeted to cortical neurons in specific cortico-subcortical loops. Novel compact laser sources and a Diffusing Wave Spectroscopy monitoring system will be developed to enable non-invasive bidirectional control of the phytochromes by two-photon excitation. NEUROPA will achieve in-lab technology validation of long-term network activity modulation and behavioural symptom alleviation in Huntington’s and Alzheimer’s disease mouse models. To achieve this, we have assembled a consortium of phytochrome engineering, gene delivery, laser photonics and detection experts, cellular, in vivo and behavioural neuroscientists, together with drug discovery expertise. We envisage progress to human use within 15 years.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores